$LYEL SEC Filings

Filed On	Filing
13 Oct 2026	Form 4: Aguirre Jarrad Mattieu, Chief Medical Officer Sold 422 shares ($3.64K)
10 Sep 2026	Form 4: Aguirre Jarrad Mattieu, Chief Medical Officer Granted 47,500 Option (right to buy)
10 Sep 2026	Form 3: Aguirre Jarrad Mattieu, Chief Medical Officer Holds 20,279 shares of Common Stock
10 Sep 2026	Form 4: Shook David, Chief Medical Officer Sold 500 shares ($6.35K)
10 Sep 2026	8-K: Other Events Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
25 Aug 2026	Form 4: Seely Lynn, Director Sold 9,589 shares ($149K)
25 Aug 2026	Form 4: Hill Stephen J., Chief Operating Officer Sold 989 shares ($15.4K)
25 Aug 2026	Form 4: Lee Gary K., Chief Scientific Officer Sold 1,457 shares ($22.6K)
14 Aug 2026	SCHEDULE 13G/A
11 Aug 2026	Form 4: Bulis Veronica Sanchez, VP, Corporate Controller Sold 621 shares ($8.91K)
11 Aug 2026	Form 4: Lee Gary K., Chief Scientific Officer Sold 131 shares ($1.88K)
11 Aug 2026	Form 4: Hill Stephen J., Chief Operating Officer Sold 89 shares ($1.28K)
11 Aug 2026	Form 4: Seely Lynn, Director Sold 390 shares ($5.59K)
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
27 Jul 2026	Form 4: Innovative Cellular Therapeutics Holdings Ltd, 10% owner Disposed of 44,000 shares (Other Transaction)
27 Jul 2026	Form 4: Innovative Cellular Therapeutics Holdings Ltd, 10% owner Disposed of 38,500 shares (Other Transaction)
21 Jul 2026	EFFECT
20 Jul 2026	Form 4: Innovative Cellular Therapeutics Holdings Ltd, 10% owner Sold 10 shares ($137)
17 Jul 2026	CORRESP

Comments